Abstract
Circulating monocytes from hypertensive patients show elevated secretion patterns of pro-inflammatory cytokines, an increased expression of adhesion molecules, and an increased adhesion to vascular endothelial cells. We tested the hypothesis that telmisartan, an angiotensin II type 1 (AT1) receptor antagonist, reduces the activation of circulating monocytes from hypertensive patients and diminishes the monocyte–endothelial cell adhesion. Monocytes of 20 hypertensive patients and 20 normotensive controls were isolated by density gradient centrifugation and Dynabeads, and the monocyte adhesion to human aortic endothelial cell monolayers was measured by adhesion assays. To characterize monocyte activation we assessed the expression of activity-related cell surface markers that are also involved in monocyte adhesion to endothelial cells, such as CD11a/b and CD54, as well as the chemokine receptors CCR1, CCR2 and CCR5 before and after telmisartan therapy using flow cytometry. Spontaneous adhesion of monocytes from hypertensive patients and the adhesion after stimulation with angiotensin II were significantly increased compared with those in normotensive controls (p<0.05). Treatment of hypertensive patients with the AT1 receptor antagonist telmisartan significantly diminished the adhesion of circulating monocytes to human endothelial cells (p=0.02) despite the increase in the expressions of CD11b, CD54 and CCR5 after telmisartan therapy. Reducing monocyte adhesion may be a novel beneficial effect of the AT1 receptor antagonist telmisartan helping to prevent vascular alterations in hypertension. The mechanism of action remains to be elucidated, since reduction in monocyte adhesion was not attributable to changes in adhesion molecule expression.
Similar content being viewed by others
Article PDF
References
Simon A, Levenson J : Stratification of vascular risk in hypertension and therapeutic perspective. Am J Hypertens 1995; 8: 45–48.
Tummala PE, Chen X-L, Sundell CL, et al: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223–1229.
Schulman IH, Zhou MS, Raij L : Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J Hypertens Suppl 2006; 24: S45–S50.
Ross R : Atherosclerosis—an inflammatory diseases. N Engl J Med 1999; 340: 115–126.
Hartwell DW, Wagner DD : New discoveries with mice mutant in endothelial and platelet selectins. Thromb Haemost 1999; 82: 850–857.
Tedder TF, Steeber DA, Chen A, Engel P : The selectins: vascular adhesion molecules. FASEB J 1995; 9: 866–873.
Imhof BA, Aurrand-Lions M : Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004; 4: 432–444.
Butcher EC : Leukocyte-endothelial cell recognition: three (or more) steps to specifity. Cell 1991; 67: 1033–1036.
Alexander RW : Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response; a new perspective. Hypertension 1995; 25: 155–161.
McCarron RM, Wang L, Siren AL, Spatz M, Hallenbeck JM : Monocyte adhesion to cerebromicrovascular endothelial cells derived from hypertensive and normotensive rats. Am J Physiol 1994; 267: H2491–H2497.
Libby P : What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001; 88: 3J–6J.
Dörffel Y, Lätsch C, Stuhlmüller B, et al: Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113–117.
Tanaka C, Mannami T, Kamide K, et al: Single nucleotide polymorphisms in the interleukin-6 gene associated with blood pressure and atherosclerosis in a Japanese general population. Hypertens Res 2005; 28: 35–41.
Dörffel Y, Franz S, Pruß A, et al: Preactivated monocytes from hypertensive patients as a factor for atherosclerosis? Atherosclerosis 2001; 157: 151–160.
Kranzhofer R, Browatzki M, Schmidt J, Kubler W : Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826–828.
Szabo C, Pacher P, Zsengeller Z, et al: Angiotensin II–mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 2004; 10: 28–35.
Vazquez-Oliva G, Fernandez-Real JM, Zamora A, Vilaseca M, Badimon L : Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive patients. J Hum Hypertens 2005; 19: 457–462.
Sanada H, Midorikawa S, Yatabe J, et al: Elevation of serum soluble E- and P-selectin in patients with hypertension is reversed by benidipine, a long-acting calcium channel blocker. Hypertens Res 2005; 28: 871–878.
Mervaala EM, Muller DN, Park JK, et al: Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999; 33: 389–395.
Brasier AR, Recinos A, Eledrisi MS : Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257–1266.
Dandona P, Kumar V, Aljada A, et al: Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leucocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin Endocrinol Metab 2003; 88: 4496–4501.
Uchida H, Nakamura Y, Kaihara M, et al: Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545–550.
Sasaki DT, Dumas SE, Engleman EG : Discrimination of viable and non-viable cells using propidium iodide in two color immunofluorescence. Cytometry 1987; 8: 413–420.
Dörffel Y, Bresan V, Stuhlmüller B, Dörffel WV, Pruss A, Scholze J : Candesartan—an inhibitor of monocyte activation in hypertensive patients? Perfusion 2002; 15: 96–101.
Hahn AWA, Jonas F, Bühler FR, Resink TJ : Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347: 178–180.
Wingren AG, Parra E, Varga M, et al: T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995; 15: 235–253.
Heinzelmann M, Mercer-Jones MA, Gardner SA, Wilson MA, Polk HC : Bacterial cell wall products increase monocyte HLA-DR and ICAM-1 without affecting lymphocyte CD18 expression. Cell Immunol 1997; 176: 127–134.
Hmama Z, Knutson KL, Herrera-Velit P, Nandan D, Reiner NE : Monocyte adherence induced by lipopolysaccharide involves CD14, LFA-1, and cytohesin-1. J Biol Chem 1999; 274: 1050–1057.
Issekutz TB : In vivo blood monocyte migration to acute inflammatory reactions, IL1α, TNF-α, IFN-γ, and C5a utilizes LFA-1, Mac-1, and VLA-4. J Immunol 1995; 154: 6533–6540.
Greenfield EA, Nguyen KA, Kuchroo VK : CD28/B7 costimulation: a review. Crit Rev Immunol 1998; 18: 389–418.
Luster AD : Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436–445.
Ishibashi M, Hiasa K, Zhao Q, et al: Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodelling. Circ Res 2004; 94: 1203–1210.
Zernecke A, Liehn EA, Gao J-L, Kuziel WA, Murphy PM, Weber C : Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 2006; 107: 4240–4243.
Dörffel Y, Wallukat G, Bochnig N, et al: Agonistic AT1 receptor autoantibodies and monocyte stimulation in hypertensive patients. Am J Hypertens 2003; 16: 827–833.
DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR : Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335–1341.
Madej A, Okopien B, Kowlski J, Haberka M, Herman ZS : Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep 2005; 57: 878–881.
Roep BO, Heidenthal E, de Vries RRP : Soluble forms of intercellular adhesion molecule-1 in insulin dependent diabetes mellitus. Lancet 1994; 343: 1540–1543.
Hackmann A, Abe Y : Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334–1338.
Fliser D, Buchholz K, Haller H, European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators : Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103–1107.
Prasad A, Koh KK, Schenke WH, et al: Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 2001; 142: 248–253.
Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE : Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension 2001; 37: 587–593.
Thomas TH, Advani A : Inflammation in cardiovascular disease and regulation of the actin cytoskeleton in inflammatory cells: the actin cytoskeleton as a target. Cardiovasc Hematol Agents Med Chem 2006; 4: 165–182.
Bayer AL, Heidkamp MC, Patel N, Porter MJ, Engman SJ, Samarel AM : Pyk2 expression and phosphorylation increases in pressure overload–induced left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2002; 283: H695–H706.
Rocic P, Griffin TM, McRae CN, Lucchesi PA : Altered Pyk2 phosphorylation by Ang II in hypertensive vascular smooth muscle. Am J Physiol Heart Circ Physiol 2003; 282: H457–H465.
Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB : Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645–651.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Syrbe, U., Moebes, A., Scholze, J. et al. Effects of the Angiotensin II Type 1 Receptor Antagonist Telmisartan on Monocyte Adhesion and Activation in Patients with Essential Hypertension. Hypertens Res 30, 521–528 (2007). https://doi.org/10.1291/hypres.30.521
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.521
Keywords
This article is cited by
-
Immunomodulation and immunopharmacology in heart failure
Nature Reviews Cardiology (2024)
-
Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise
American Journal of Cardiovascular Drugs (2019)
-
Understanding the Two Faces of Low-Salt Intake
Current Hypertension Reports (2017)
-
DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing
BMC Bioinformatics (2016)
-
A CCR2/CCR5 Antagonist Attenuates an Increase in Angiotensin II-Induced CD11b+ Monocytes from Atherogenic ApoE−/− Mice
Cardiovascular Drugs and Therapy (2009)